NEWARK, N.J., Feb. 3, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced the formation of BioNeutral Services, Inc., a wholly owned subsidiary of BioNeutral Group, Inc., and the appointment of Frank Battafarano as the Chairman and Chief Executive Officer of the new division.
BioNeutral Services will market and distribute a family of BioNeutral products that represent a new generation of specialty anti-microbial disinfectants, cleaning agents and neutralizers of odors and harmful gases. The company, based in Kentucky, is a specialty cleaning solutions company servicing the healthcare industry and providing environmentally friendly solutions to everyday care. Fatal hospital acquired infections and harmful bacteria are a serious problem in the healthcare industry today. BioNeutral has identified a solution which eliminates the main causes of these life threatening issues by treating the environment around the patient. In addition to reducing fatalities, the use of the products is expected to reduce healthcare cost.
Prior to joining BioNeutral Services, Mr. Battafarano was Chief Operating Officer of Kindred Healthcare, Inc., a healthcare services company with annual revenues of over $4.2 billion. Mr. Battafarano has held several senior management positions during his 30 years in the healthcare industry and has a thorough understanding of this market.
"I am pleased to join BioNeutral Services, and I am excited about providing 'game changing' products that will help in the elimination of serious bacterial infections in the healthcare industry," said Frank Battafarano, Chairman and Chief Executive Officer of BioNeutral Services.
"The BioNeutral board and I are extremely pleased with the inauguration of BioNeutral Services under the direction of its new CEO, Frank Battafarano," said Stephen J. Browand, Chairman, President & CEO of BioNeutral Group Inc. "The formation of our Services division and the appointment of Frank Battafarano as its Chairman and CEO are integral parts of the ongoing ground work being put in place to aggressively pursue national opportunities as they unfold. Frank has extensive experience and a broad understanding of the healthcare market which will be invaluable for the success of the entire group. We are very pleased to welcome Frank and the Services division to the BioNeutral team."
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
SOURCE BioNeutral Group, Inc.